Swiss medtech startup MoleSense has received €156,000 (CHF 150,000) from Venture Kick to develop wearables that monitor inflammatory proteins and steroid hormones through sweat analysis in high-risk pregnancies.
The EPFL spin-off’s technology targets preterm birth prevention by providing continuous, non-invasive monitoring of biochemical markers. When premature rupture of membranes occurs, the device aims to help clinicians quantify infection risk versus premature delivery complications.
The wearable combines molecular data collection with machine learning algorithms to provide real-time insights for early diagnosis and intervention decisions. The company describes its device as “wear and forget” technology that eliminates the need for repeated invasive testing.
MoleSense targets eight million high-risk pregnancies annually across Switzerland, Europe, and the United States, entering what the company estimates as a $110 billion women’s healthcare device market. Initial deployment will focus on high-risk pregnancy centers, starting with CHUV in Switzerland.
The €156,000 funding will support validation studies and regulatory pathway development for early market entry. The company has not disclosed timeline details for clinical trials or regulatory submissions.
